NCT02047175已完成1 期
A Randomized, Open-label, Multiple-dose, Two-arm, One-sequence • Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration Telmisartan/S-amlodipine and Rosuvastatin in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 64
- 试验地点
- 1
- 主要终点
- Cmax,ss of Telmisartan/S-Amlodipine
研究概览
简要总结
The purpose of this study is to evaluate the drug-drug interaction of CKD-346(Telmisartan/S-Amlodipine, Rosuvastatin)
详细描述
A randomized, open-label, multiple-dose, two-arm, one-sequence · crossover study to evaluate the safety and pharmacokinetics after oral concurrent administration telmisartan/s-amlodipine and rosuvastatin in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participant is a male or female between 20 and 45 years of age (inclusive) at the pre-study (screening)
- •Participant who has a body weight that is >55kg(male) or >50kg(female) with ideal body weight of 80-120% (ideal body weight) = {Height(cm) - 100} * 0.9
- •If female, must include more than one among the items
- •The menopause (there is no natural menses for at least 2 years)
- •Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or other methods of infertility condition)
- •The male partner infertility before screening (Demonstrated azoospermia after vasectomy)and if this man is the only partner of the female subject.
- •you are using one of the following contraceptive measure for 3 months before screening, and Necessarily you agree that used continuously contraceptive measure during the clinical trial and for 1 month after the final dosing investigational product.(But, should not use a device of contraception or oral contraceptive drug that containing a hormonal caused telmisartan, s-amlodipine, atorvastatin calcium drug interactions during the clinical trials)
- •Abstinence.
- •Physical interrupt method (such as a condom, contraceptive diaphoretic or cervical cap)
- •In case of women of childbearing age, the serum β-hCG pregnancy test is negative before taking the investigational product, and urine β-hCG test is negative before taking the investigational product.
- •If men has sexual life with women of childbearing age, Necessarily he agrees that use condoms during clinical trials and do not sperm donation during clinical trials and until one month after the final dosage of investigational products
- •Those who fully understand about this clinical trial after enough hearing, and then decided to join the clinical trials by themselves and to comply with the precautions written consent.
排除标准
- •The subject has a previous history of any clinically significant cardiovascular, pulmonary, renal, endocrine, hematological, gastro-intestinal, neurological, psychiatric, or malignancy.
- •Have a gastrointestinal disease history that can affect drug absorption (Crohn's disease, ulcers, etc.) or surgery (except simple appendectomy or hernia surgery).
- •Hypersensitivity reaction to drug or clinically significant hypersensitivity reaction in the history of Investigational drugs (telmisartan, s-amlodipine or rosuvastatin calcium) or additives.
- •An impossible one who participates in clinical trial including screening tests(medical history taking, V/S, physical examination, 12-lead ECG, blood & urine laboratory test result)
- •Defined by the following laboratory parameters:
- •Hemoglobin < 13.0 g/dL(male), Hemoglobin < 12.0 g/dL(female)
- •AST, ALT> 1.25* upper limit of normal range
- •Total bilirubin > 1.5* upper limit of normal range
- •CPK > 1.5* upper limit of normal range
- •eGFR(using by MDRD method) < 60 mL/min/1.73m2
- •Sitting SBP > 150 mmHg or < 90 mmHg, Sitting DBP> 100 mmHg or < 50 mmHg , after 5minuts break.
- •Drug abuse or have a history of drug abuse showed a positive for urine drug test.
- •Female Participant is pregnant or lactating
- •A heavy caffeine consumer(caffeine>5cups/day), alcohol consumer(alcohol>210g/week), or smoker(cigarette>10cigarettes/day)
- •Participation in any other study and have received any other investigational drug or device within 90 days prior to study treatment.
- •Administration of drug metabolizing enzyme inducers or inhibitors such as barbitals within 30 days prior to the first dosing.
- •Blood donation (1 unit or more) within 60 days prior to study treatment or plasma donation within 30 days prior to study treatment.
- •Taking foods containing grapefruit within 7 days before the beginning of study treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7 days before the beginning of study treatment)
- •Subject takes ethical drug or herbal medicine within 14days, OTC or vitamins within 7days before the beginning of study treatment.
- •An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason.
研究组 & 干预措施
A(Telmisartan/S-Amlodipine)
Experimental
A(Telmisartan/S-Amlodipine)
: Telmisartan/S-Amlodipine 40/2.5mg 2T for 9days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 5days
干预措施: Telmisartan/S-Amlodipine (Drug)
A(Telmisartan/S-Amlodipine)
Experimental
A(Telmisartan/S-Amlodipine)
: Telmisartan/S-Amlodipine 40/2.5mg 2T for 9days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 5days
干预措施: Telmisartan/S-Amlodipine + Rosuvastatin (Drug)
B(Rosuvastatin)
Experimental
B(Rosuvastatin)
: Rosuvastatin 20mg 1T for 5days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 9days
干预措施: Rosuvastatin (Drug)
B(Rosuvastatin)
Experimental
B(Rosuvastatin)
: Rosuvastatin 20mg 1T for 5days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 9days
干预措施: Telmisartan/S-Amlodipine + Rosuvastatin (Drug)
结局指标
主要结局
Cmax,ss of Telmisartan/S-Amlodipine
时间窗: 0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h
AUCt,ss of Telmisartan/S-Amlodipine
时间窗: 0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h
Cmax,ss of Rosuvastatin
时间窗: 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h
AUCt,ss of Rosuvastatin
时间窗: 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h
次要结局
- R of Telmisartan/S-Amlodipine(0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h)
- Tmax,ss of Telmisartan/S-Amlodipine(0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h)
- T1/2 of Rosuvastatin(0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h)
- Vd/F of Rosuvastatin(0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h)
- CL/F of Rosuvastatin(0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h)
- R of Rosuvastatin(0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h)
- T1/2 of Telmisartan/S-Amlodipine(0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h)
- CL/F of Telmisartan/S-Amlodipine(0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h)
- Vd/F of Telmisartan/S-Amlodipine(0, 0.33, 0.66, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24h)
- Tmax,ss of Rosuvastatin(0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24h)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult VolunteersHypertension With HyperlipidemiaNCT03461081Jeil Pharmaceutical Co., Ltd.32
已完成
1 期
Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.Essential HypertensionHyperlipidemiaNCT01842256Chong Kun Dang Pharmaceutical24
已完成
1 期
CKD-828 Drug Interaction Study (Telmisartan)Healthy Male VolunteersNCT01356017Chong Kun Dang Pharmaceutical32
已完成
1 期
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150Type 2 DiabetesNCT04334213Chong Kun Dang Pharmaceutical48
已完成
1 期
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)Type 2 Diabetes MellitusNCT04431687Chong Kun Dang Pharmaceutical48